Prevail Therapeutics prevailtherapeutics.com


Public list: Pharma Startups (6570) Neuroscience Startups (947)

Prevail Therapeutics (NASDAQ: PRVL) is a gene therapy company developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases.

Prevail Therapeutics (NASDAQ: PRVL) is a gene therapy company developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases.

Company (IPO / Went public)

Phone: 917-336-9310

Fax:

430 East 29th Street
Suite 940
New York, 10016
New York, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Prevail Therapeutics $135M Jun 20, 2019

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Prevail Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Adage Capital ManagementAsset/Investment ManagementBoston, Massachusetts, United StatesSeries B, Series A
BVF PartnersVenture CapitalSan Francisco, California, United StatesSeries B, Series A
AbbVie Biotech VenturesCorporate VentureLake Forest, Illinois, United StatesSeries B
Boxer CapitalCorporate VentureWindermere, Florida, United StatesSeries B, Series A
Alexandria Venture InvestmentsCorporate VenturePasadena, California, United StatesSeries B, Series A
See all 14 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)